Radotinib(IY-5511)

Radotinib(IY-5511)

Catalog Number:
L002371285APE
Mfr. No.:
APE-B5846
Price:
$292
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Radotinib(IY-5511) is a novel and selective Bcl-Abl tyrosine kinase inhibitor. [1]
          Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).
          In vitro, radotinib couples to Bcr-Abl and reduce the phosphorylation of Bcr-Abl target protein CrkL. The pre-clinical studies shows superiority of radotinib to imatinib in both wild-type and mutant BCR-ABL1 positive CML cell lines. [1]
          In a phase I clinical trial, dose up to 1000 mg/day of radotinib exhibits no dose-limiting toxicities. Phase II study proves radotinib to be an effective and well tolerated in chronic phase-chronic myeloid leukemia patients with resistance and/or intolerance to Bcr-Abl1 tyrosine kinase inhibitors. [1]

      • Properties
        • Alternative Name
          (Z)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyrazin-2-yl)pyrimidin-2-yl)amino)benzimidic acid
          CAS Number
          926037-48-1
          Molecular Formula
          C27H21F3N8O
          Molecular Weight
          530.5
          Appearance
          A solid
          Purity
          99.43%
          Solubility
          ≥26.55 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
          Storage
          Store at -20°C

          * For Research Use Only

    We Also Recommend

    KNK437

    $244

    SNG-1153

    $244

    TH287

    $196

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.